Thrombophilia and fetal loss

Blood Reviews

Volumn 11, Issue 2, 1997, Pages 72-79

  Brenner, B ^a   Blumenfeld, Z ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; FETUS; FETUS WASTAGE; HUMAN; HYPERHOMOCYSTEINEMIA; PLACENTA CIRCULATION; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; THROMBOPHILIA; VASCULAR DISEASE;

EID: 0030761729     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90013-8     Document Type: Article

References (82)

1. Lockshin MD. Lupus pregnancy. Clin Rheum Dis 1985; 11: 611-632.
2. Haywood L, Brown MD. Antiphospholipid antibodies and recurrent pregnancy loss. Clin Obstet Gynecol 1991; 34: 1-17.
3. Blumenfeld Z, Weiner Z, Lorber M, Sujov P, Thaler I. Anticardiolipin antibodies in patients with recurrent pregnancy wastage: treatment and uterine blood flow. Obstet Gynecol 1991; 78: 584-589.
4. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia I. Thromb Haemostas 1996; 76: 651-662.
5. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia II. Thromb Haemostas 1996; 76: 824-834.
6. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
7. Yetmah DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996; 66: 540-546.
8. Matzner W, Chong P, Xu G, Ching W. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions. J Reprod Med 1994; 39: 27-30.
9. Sher G, Feinman M, Zoures C, Kuttner G, Maassarani G, Salem R. High fecundity rates following in-vitro fertilization and embryo transfer treated with heparin and aspirin. Hum Reprod 1994; 9: 2278-2283.
10. Gilman-Sachs A, Lubinski J, Beer AE, Brend S, Beaman KD. Patterns of antiphospholipid antibody specificities. J Clin Lab Immunol 1991; 35: 83-88.
11. Kutteh WH, Lyda LE, Abraham SM, Wacholtz MC. Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus. Fertil Steril 1993; 60: 449-455.
12. Bronson R. Immunology and reproductive medicine. Hum Reprod 1995; 10: 755-757.
13. Scott JR, Rote NS, Branch DW Immunologic aspects of recurrent abortion and fetal death. Obstet Gynecol 1987; 70: 645-656.
14. Branch DW, Scott JR, Kochenour NK, Hershgold M. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313: 1322-1326.
15. Brnach DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73: 541-545.
16. Kochenour NK, Branch DW, Rote NS, Scott JR. A new postpartum syndrome associated with antiphospholipid antibodies. Obstet Gynecol 1987; 69: 460-468.
17. Lockshin MD, Qamar T, Druzin ML, Goei S. Antibody to cardiolipin, lupus anticoagulant and fetal death. J Rheumatol 1987; 14: 259-262.
18. Triplett DA. Antiphospholipid antibodies: proposed mechanisms of action. Am J Reprod Immunol 1992; 28: 211-215.
19. Weiner Z, Lorber M, Blumenfeld Z. Umbilical and uterine artery flow velocity waveforms in pregnant women with systemic lupus erythematosis treated with aspirin and glucocorticosteroids. Am J Reprod Immunol 1992; 28: 168-171.
20. Love PE, Santuro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non SLE disorders. Ann Intern Med 1990; 112: 682-698.
21. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-520.
22. Griffin JH, Evart B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373.
23. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614.
24. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to actived protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
25. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
26. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
27. 506-Gln mutation of factor V gene. Thromb Haemostas 1996; 75: 522-523.
28. Zivelin A, Griffin JH, Xu X et al. A single genetic origin for a common caucasian risk factor for venous thrombosis. Blood 1997; 89: 397-402.
29. Griffin JH, Evart B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1994.
30. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
31. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-213.
32. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal Fr. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
33. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C resistance in patients with lupus anticoagulants. Thromb Haemostas 1995; 74: 797-798.
34. Borrell M, Sala N, de Castellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemostas 1992; 68: 268-272.
35. Zangvill E, Jabareen A, Lanir N, Brenner B. Resistance to activated protein C antiendothelial antibodies and other markers of thrombophilia in patients with antiphospholipid antibodies syndrome. Br J Haematol 1996 (suppl 2) 93: 315 (Abst).
36. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996; 92: 489-490.
37. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916.
38. Brenner B, Mandel H, Lanir N et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997, in press.
39. Brenner B, Lanir N, Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 1996; 92: 999-1001.
40. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies and fetal loss. N Engl J Med 1991; 325: 1063-1066.
41. Out HJ, Kooijman CD, Bruise HW, Derksen R. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynaecol Reprod Biol 1991; 41: 179-184.
42. Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica 1993; 78: 313-318.
43. Sanson BJ, Friederich PW, Simioni P et al. The risk of abortion and stillbirth in antithrombin-protein C- and protein S-deficient women. Thromb Haemostas 1996; 75: 387-388.
44. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-141.
45. De Stefano V, Leone G, De Carolis S et al. Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemostas 1988; 59: 193-196.
46. Brenner B. Antithrombin III and preeclampsia. Isr J Med Sci 1990; 26:121-122.
47. Samama M, Conard J, Soria J. Congenital dysfibrinogenemia and thrombosis. Fibrinolysis 1988; 2: 18-23.
48. Goodwin TM. Congenital hypofibrinogenemia in pregnancy. Obstet Gynaecol Surv 1989; 44: 157-161.
49. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on fibrinogen. Thromb Haemostas 1995; 73: 151-161.
50. Egbring R, Kroniger A, Seitz R. Factor XIII deficiency: pathogenetic mechanisms and clinical significance. Sem Thromb Haemostas 1996; 22: 419-425.
51. Rosenblatt DS. Inherited disorders of folate transport and metabolism In: Scriver CR, Beaudet AL, Sly WS, Valle DL, eds. The Metabolic and Molecular Bases of Inherited Disease, Vol 2, 7th edn. New York: McGraw-Hill, 1995: 3111-3128.
52. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle DL, eds. The metabolic and molecular bases of inherited disease, Vol 2, 7th edn. New York: McGraw-Hill, 1995; 1279-1327.
53. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698.
54. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
55. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1993; 268: 877-881.
56. Ma J, Stampfer MJ, Hennekens CH et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate. homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 3410-2416.
57. Guttormsen AB, Ueland PM. Nesthus I et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). J Clin Invest 1996; 98: 2174-2183.
58. Steegers-Theunissen RPM, Boers GHJ et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994; 43: 1475-1480.
59. Wouters MGAJ, Boers GHJ, Blom JH et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993; 60: 820-825.
60. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1036.
61. Gandrille S, Greengard JS, Alhenc-Gelas M et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C deficient patients. Blood 1995; 86: 219-225.
62. Brenner B, Zivelin A, Lanir N, Greengard JS, Griffin JH, Seligsohn U. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C deficient newborn with massive thrombosis. Blood 1996; 88: 877-880.
63. Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3519.
64. Mandel H, Brenner B, Berant M et al. Coexistence of hereditary homocysteinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996; 334: 763-768.
65. Brenner B, Vulfsons SL, Lanir N, Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden - impact on thrombotic diathesis. Br J Haematol 1996; 94: 166-167.
66. Dekker GA, de Vries JIP, Doelitzsch PM et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-1048.
67. Saleh AA, Bottoms SF, Welch RA, Ali AM, Mariona FG, Mammen EF. Preeclampsia, delivery, and the hemostatic system. Am J Obstet Gynecol 1987; 157: 331-336.
68. Brenner B, Zwang E, Bronstein M, Seligsohn U. von Willebrand factor multimer patterns in pregnancy induced hypertension. Thromb Haemostas 1989; 62: 715-717.
69. Dizon-Townson DS, Nelson LM. Katrina Easton BS, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 155: 902-905.
70. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107.
71. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995; 92: 850-854.
72. Lubbe WF, Palmer SJ, Butler WS, Liggins GC. Fetal survival after prednisone suppression of maternal lupus anticoagulant. Lancet 1983; 1: 1361-1363.
73. Elder MG, de Swiet M, Robertson A, Elder MA, Flloyd E, Hawkins DF. Low-dose aspirin in pregnancy. Lancet 1988; 1: 410-412.
74. Balasch J, Carmona F, Lopez-Soto A et al. Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Hum Reprod 1993; 8: 2234-2239.
75. Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin N. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am Obstet Gynecol 1993; 169: 1411-1417.
76. Orvieto R, Achiron A, Ben-Rafael Z, Achiron R. Intravenous immunoglobulin treatment for recurrent abortions caused by antiphospholipid antibodies. Fertil Steril 1991; 56: 1013-1020.
77. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069-3073.
78. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131-136.
79. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
80. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-257.
81. Younis JS, Ohel G, Brenner B, Ben-Ami M. Familial thrombophilia - the scientific rationale for thrombophylaxis in recurrent pregnancy loss. Hum Reprod 1997; in press.
82. Jabareen A, Blumenfeld Z, Younis J, Brenner B. Prevention of recurrent fetal loss and gestational thromboembolism by enoxaparin. Thromb Haemostas 1997; in press.